Is SpyGlass Pharma financially healthy?
Not really
SpyGlass Pharma carries heavy debt: it would take 8.3 years of earnings to pay it off.
The numbers behind it
Net debt / EBITDA8.3 years
Cash vs. debt$96M vs. $2M
Current ratio38.0×Short-term assets for each $1 of bills due within a year
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about SpyGlass Pharma
Data as of Nov 13, 2026.